Kearney, NE., - SCORR Marketing, a global health science marketing and communications firm, in association with Applied Clinical Trials, has released the results of a comprehensive survey on the use of paperless processes in clinical trials. The report describes which paperless processes have largely been implemented and the biggest benefits that have been realized. It also pinpoints which stakeholders are most reluctant to implement paper processes and forecasts what the future holds for these processes. “In the survey, we discovered that the users of paperless processes felt strongly that these processes have improved data collection as well as data and document quality,” said Cliff Echols, director of market intelligence at SCORR. “However, some users, particularly those from academic institutions, report that paperless processes haven’t reduced the need for data entry as much as they had hoped.” The survey also gathered information on current levels of paperless data collection, the benefits and challenges stemming from eClinical processes, resistance and hurdles concerning paperless trials and predictions about the future of the practice. Respondents included individuals from across the globe, representing CROs, pharmaceutical companies, academic institutions, consultancies, service providers, research sites, hospitals and medical device companies. “We found that the cost of technology and fear of change were the two greatest hindrances to the adoption of paperless processes,” said Lisa Henderson, editor in chief at Applied Clinical Trials, a part of the life sciences unit of UBM. “However, many respondents, particularly those working within a CRO, believe that there will still be a dramatic increase in their company’s use of paperless processes over the next three years.” Download the full report at scorrmarketing.com. About SCORR Marketing SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.